

CSD/BSE&NSE/2021-22

October 25, 2021

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Statement of Deviation(s) or variation(s) for the quarter ended 30th September, 2021 under Regulation 32 of SEBI (LODR) Regulations, 2015.


.....

With reference to the above subject, please find enclosed statement confirming that there were no deviation(s) or variation(s) in the use of proceeds, from the objects for which funds were raised through the preferential issue made by the Company, for the quarter ended 30th September, 2021.

We request you to take this on your record.

Thanking you,

Yours faithfully,
For **Suven Life Sciences Limited**



Shrenik Soni
Company Secretary
Encl.: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

Statement of Deviation / Variation in utilisation of funds raised						
Name of listed entity	Suven Life Sciences Limited					
Mode of Fund Raising	Preferential Issue					
Date of Raising Funds	02/04/2021					
Total Amount Raised as on 30/09/2021 (in Rs. crores)	Rs. 46.8260 Crore (including the amount paid towards 25% of consideration amount of warrants) out of total Rs. 147.6417 Crore of preferential issue size.					
Report filed for Quarter ended	30 th September, 2021					
Monitoring Agency	Not Applicable					
Monitoring Agency Name, if applicable	Not Applicable					
Is there a Deviation / Variation in use of funds raised	No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable					
If Yes, Date of shareholder Approval	Not Applicable					
Explanation for the Deviation / Variation	Not Applicable					
Comments of the Audit Committee after review	Nil					
Comments of the auditors, if any	Not Applicable					
Objects for which funds have been raised and where there has been a deviation, in the following table	The proceeds of the preferential issue shall be utilized to meet the funding requirements of the company for undertaking Research & Development activities, general corporate purposes and working capital requirements.					
Original Object	Modified Object, if any	Original Allocation (A)	Modified allocation, if any	Funds Utilised (B)	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
The proceeds of the preferential issue shall be utilized to meet the funding requirements of the company for undertaking Research & Development activities, general corporate purposes and working capital requirements.	Not Applicable	Rs. 46.8260 Crore	Not Applicable	Rs. 41.7655 Crore	Not Applicable	The difference amount (A-B) of Rs. 5.0605 Crore is yet to be utilized as on 30/09/2021.

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or*
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or*
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc*

For Suven Life Sciences Limited

M. Mohan

M. Mohan Kumar
Chief Financial Officer

